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Objective: This paper examines the Intellectual Property (IP) landscape for non‐
invasive prenatal testing (NIPT) in three key regions: the United States; Europe, with
particular focus on the United Kingdom; and Australia.
Method: We explore the patent law issues against the commercial and healthcare
environment in these regions and consider the implications for development and
implementation of NIPT.
Results: There are many patents held by many parties internationally, with litigation
over these patents ongoing in many countries. Importantly, there are significant inter-
national differences in patent law, with patents invalidated in the USA that remain
valid in Europe. Despite the many patents and ongoing litigation, there are multiple
providers of testing internationally, and patents do not appear to be preventing
patient access to testing for those who can pay out of pocket.
Conclusion: The patent situation in NIPT remains in a state of flux, with uncertainty
about how patent rights will be conferred in different jurisdictions, and how patents
might affect clinical access. However, patents are unlikely to result in a monopoly for
a single provider, with several providers and testing technologies, including both pub-
lic and private sector entities, likely to remain engaged in delivery of NIPT. However,
the effects on access in public healthcare systems are more complex and need to be
monitored.1 | INTRODUCTION
Non‐invasive prenatal genetic testing (NIPT) based on cell free DNA
sequencing technology has developed rapidly, and is being incorpo-
rated into prenatal screening globally. Intellectual property rights,
notably patents, have had, and continue to have, an important
influence.1,2 Key commercial players hold patent portfolios, and most
have engaged in extensive litigation and licensing.3,4 Patents have
played a key role in shaping the development and delivery of NIPT,- - - - - - - - - - - - - - - - - - - - - - - - - -
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This paper examines the IP landscape for NIPT in three key regions:
the United States; Europe, with particular focus on the United
Kingdom; and Australia. We explore the patent law issues in the
context of commercial and healthcare systems in these regions and
consider the implications for development and implementation of
NIPT. We focus on these jurisdictions because, although they do not
represent all countries where NIPT is offered, they represent a cross
section of the different legal approaches, different patent office- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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What's already known about this topic?
2 HAWKINS ET AL.practices and application of patent criteria, key markets for commer-
cial providers, and also the different types of healthcare systems in
which NIPT currently operates.5
• Non‐invasive prenatal testing (NIPT) is a rapidly growing
field of testing, with significant commercial involvement
and a number of relevant patents.
• The patents in this field have caused concern about
implications for access to testing.
• Recent court decisions and company acquisitions have
settled some of these patent disputes and abated some
of the concerns about access to testing in the United
States, but significant controversy continues in the rest
of the world.
What does this study add?
• This study sets out the current law, including recent
cases relevant to NIPT, and considers the implications
of this law against the commercial environment in the
United States, Europe, and Australia, for the future
development and delivery of NIPT internationally.2 | KEY PATENTS, PRODUCTS, AND
PLAYERS
One patent family has been the subject of particular attention in the
literature.6 An application for US Patent 6 258 540 was filed in
1997. It gave rise to a family of patents in the United States, Australia,
and various European countries in broadly similar terms. We use the
term “540” to describe this patent family. The invention claimed in
540 arose from research carried out by Dennis Lo and colleagues.
The patent was originally owned by Oxford University Innovation,
exclusively licensed (except for use in Hong Kong and China), and
assigned to Sequenom.7 This is the broadest NIPT patent, claiming
methods of using cell‐free fetal DNA (cffDNA). If valid, it arguably
covers virtually every method of performing NIPT using cffDNA
analysis.
Sequenom began offering NIPT in the United States under the
brand name MaterniT21 in 2011.The other major entities involved in
early NIPT development and delivery in the United States were
Verinata Health (Verifi), Ariosa Diagnostics (Harmony), and Natera
(Panorama).1 In an illustration of the perceived value of NIPT and
industry consolidation, Sequenom was acquired by LabCorp, Verinata
by Illumina, and Ariosa by Roche. These and other entities involved in
NIPT development and delivery have patents, or pending applications,
which cover narrower aspects of NIPT, for example, certain types of
sequencing techniques or algorithms.
In December 2014, Sequenom and Illumina—arguably the two
most prominent companies involved in the development and delivery
of NIPT globally—settled their patent disputes by cross‐licensing their
patents, including 540.8 Through the agreement, Illumina obtained
worldwide rights to use the pooled patents for kit tests for NIPT
and to license third‐party laboratories to develop and deliver their
own laboratory‐developed NIPT. Sequenom and Illumina also retained
the right to develop and deliver their own laboratory‐developed
NIPT.9
There are growing numbers of public and private providers of NIPT
globally.10 Ariosa (Roche) and Natera remain the major competitors of
Sequenom and Illumina in the United States. Premaitha (now Yourgene
Health) is a significant late UK entrant into the NIPT market, with its
IONA test, offered in Europe and various other countries, but not the
United States. BGI Health (Nifty) and Berry Genomics (BambniTest),
based in China, are also important players in the NIPT market outside
of the United States. Genesis Genetics also offers NIPT in the United
Kingdom, based on Verifi technology (Serenity®). In Australia, the Vic-
torian Clinical Genetics Services offers NIPT using the Percept test,
based on the original Lo technology, whereas Sonic Genetics and Aus-
tralian Clinical Labs offer Harmony. As in other countries, other pro-
viders also perform NIPT.3 | PATENT LAW PRINCIPLES AND NIPT
Each patent application must be assessed on its own merits to deter-
mine validity in every jurisdiction in which it is filed. Once a patent is
granted, the patent holder has the right to enforce it against alleged
infringers. By asserting a patent, however, the patent holder provides
the opportunity for other parties to argue that the patent is in fact
invalid and should never have been granted. A number of arguments
can be raised regarding validity, such as technical questions relating
to the novelty, obviousness, and usefulness of the invention, and the
adequacy of the disclosure relative to the scope of claims. However,
it is the threshold question of whether the subject matter is inherently
patent‐eligible that has attracted most attention in recent times,
particularly in the context of DNA sequences and methods of their
use.
Until recently, it was uncontroversial to observe that the law of the
United States was more permissive towards the patentability of
genetic subject matter than Europe, with Australia taking a middle
road. However, a series of US cases has reversed this proposition,
and as a result, US law now offers significantly less expansive patent
eligibility than previously.11-14 These decisions have created uncer-
tainties because of the ambiguity of their applicability.15 In order to
fully appreciate the nuances of these decisions, it is first important
to clarify the distinction between product and method patents.
Product patents claim protection over physical entities or things
—“compositions of matter.” Such claims have been controversial in
genetics, with the primary concern being that broad product claims
vest control of all uses of the particular products in the patent holder.
Depending on how these patent rights are managed and enforced,
follow‐on research and development can be stifled. In the context of
DNA sequence claims, a patent could potentially block development
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of all or part of the sequence.16-20
In the NIPT context, however, the direct implications of product
patents are actually relatively small, as the vast majority of NIPT
patents make claims on methods. Method patent claims can have
significant impact on development and use of genetic diagnostic tests.
Indeed, a study conducted by Huys et al found that method claims
were more prone to block diagnostic uses than sequence claims.214 | PATENT PRACTICE IN THE UNITED
STATES
In the United States, patents on the BRCA1 and BRCA2 genes associ-
ated with inherited risk of breast and ovarian cancer included broad
product claims on isolated and human made DNA sequences (respec-
tively, gDNA and cDNA), as well as a variety of method claims.
Ultimately, the Supreme Court was only required to consider the
product claims, because lower courts invalidated the broad method
claims.22 The Court held in theMyriad decision that “A naturally occur-
ring DNA segment is a product of nature and not patent eligible
merely because it has been isolated, but cDNA is patent eligible
because it is not naturally occurring.”13 The Supreme Court did not
explain, however, how to determine the change required to the DNA
sequence (or other naturally occurring substance) to make it “markedly
different” 23 from its naturally occurring counterpart, and hence,
patent eligible. This question, and the broader implications of the
Myriad decision for medical biotechnology, has been the subject of a
great deal of criticism and commentary.20,24
Patent eligibility for DNA‐related methods has been narrowed
under US law by three key cases.11,14,12 The most relevant is Mayo v
Prometheus,25 which concerned claims to a method for titrating the
dose of thiopurine drugs by measuring a specific metabolite. The
Supreme Court invalidated the method claims, as merely applying a
law of nature,25and held that a process which applies a law of nature
will not be patentable unless that process has additional features
beyond those already known in the field. Mayo was not a gene patent
case, but it had important implications for DNA diagnostic method
claims in patents such as those held by Myriad, the key diagnostic
claims of which were invalidated by the lower courts. Following Mayo
and other cases, the US Patent and Trademark Office (USPTO) issued
a set of guidelines to assist examiners in determining patent eligibil-
ity.26 Examiners must now decide whether a claim is directed to a
“judicial exception” (in life sciences, a law of nature or a natural phe-
nomenon) or is “markedly different” from the exception (Step 2A). If
the claim is directed towards one of the recognised exceptions, or is
not markedly different from them, the examiner must determine
whether there are elements in the claim, alone or in combination, that
add “significantly more” than the judicial exception, going beyond well
understood, routine activities in the relevant art (Step 2B). Therefore,
following these decisions, it is substantially more difficult to patent a
diagnostic method in the United States.The limitations imposed by the Mayo line of reasoning are very
important for NIPT patents, and were tested by the US Court of
Appeals for Federal Circuit in Ariosa v Sequenom.27,28 After a
complicated route through the courts, the Federal Circuit invalidated
the patent, finding that the relevant claims were directed to naturally
occurring phenomena (Step 2A), and that the claims included no
inventive concept sufficient to transform the claimed naturally occur-
ring phenomena into a patent eligible application (Step 2B).29 The US
Supreme Court declined to review the decision of the lower court,30
so the 540 patent remains invalid in the United States, which means
that other players can offer their tests without fear of infringing this
particular patent.
In December 2018, two patents held by Illumina were invalidated
for lack of patent‐eligible subject matter.31 Illumina and Natera are
involved in litigation over a patent for NIPT library preparation.32
Future cases may arise involving other NIPT patents.5 | PATENT PRACTICE IN EUROPE
In Europe,33 a patent must be for an “invention” in order to constitute
patentable subject matter, and the European Patent Convention (EPC)
specifies that a discovery is not an invention.34 However, a useful
artefact or process that results from a discovery can constitute pat-
entable subject matter, 35,36 and it is the practical application of an
idea or discovery which leads to patentability.37 The European Patent
Office (EPO) Boards of Appeal and courts in most European countries
have taken a relatively expansive approach to patentable subject mat-
ter, but have restrictively applied patent criteria for novelty, inventive
step, and insufficient disclosure.19 In practice, this tends to mean that
patents are scrutinised closely to determine whether they are truly
new, non‐obvious, and that the disclosure of the invention is suffi-
cient to allow others to perform it, rather than a blanket exclusion
for whole classes of inventions as “natural” such as under current
US practice.38
Under current interpretation in Europe, in contrast to the United
States, isolating DNA confers sufficient distinction from its natural
state for it to be patentable. Uncertainties and divergence in the
law among European jurisdictions were directly addressed in the
provisions of the Biotechnology Directive,39 notably Article 5,
where a distinction is drawn between naturally occurring substances
and the products which result from the human effort involved in
isolating those substances from their natural environment.40 Where
a DNA sequence is isolated from the human body by means of a
technical process, the sequence (substance) per se becomes eligible
for patent protection,41 even if it is identical to that which occurs
in vivo.42 Given that these provisions codify that isolation is suffi-
cient to confer the necessary technical character for patentability,
it is unlikely that the US Myriad decision will be followed in Europe.
With regard to method claims, European cases have focused on
whether there is a technical contribution. This technical contribution
may be fairly minimal, but provided there is a technical contribution
4 HAWKINS ET AL.the invention will be patentable and not excluded subject matter “as
such.”43,44
In Europe, a patent granted by the EPO may be opposed in
proceedings at the EPO, where a patent may be struck down in whole
or in part. If that opposition is unsuccessful, the patent may also be
challenged later in national courts. The European patent in the
540 family (EP 0994963) was opposed, but was upheld in opposition
proceedings and on appeal to the Technical Board of Appeal of the
EPO.45 Unlike in the United States, the proceedings did not address
the question of subject matter eligibility. Instead, the patent was
opposed on the grounds of lack of inventive step and insufficient
disclosure. The Board of Appeal found that there was sufficient
disclosure of the invention in the patent to enable a person in the
same technical field to perform it, and that the claims in question
were not obvious and therefore inventive enough to satisfy the
patentability requirements.
The patent is now being contested in national proceedings in var-
ious European countries. A preliminary injunction was granted against
molecular diagnostic company Amedes MVZ Trägergesellschaft and a
related company performing an NIPT (based on Ariosa technology) in
Germany.46 The UK 540 patent (Lo 1) and other patents arising from
the work of Dennis Lo (Lo 2 and 3) and Stephen Quake (Quake pat-
ents) were contested by Premaitha Health, TDL Genetics, and Ariosa
Diagnostics in proceedings before the UK High Court in 2017.47 An
infringement action had been brought against these firms by Illumina,
Sequenom, and others. In counterclaim, a plethora of legal issues were
raised. The question of whether the subject matter of the 540 patent
constituted a discovery as such, rather than an invention, was
disposed of in a single paragraph.48 The patent was held not to be a
discovery, because the claims are not directed to information about
the natural world, but rather to a practical process, the detection
method.48 Nevertheless, the court found that the Lo 1 patent was
valid only in part, based on failure to satisfy some of the technical
patent criteria, and significantly narrowed the scope of the patent
Premaitha was held to infringe the Lo 1 patent with its IONA test,
although not with its alternative proposed process (the Additional
Alternative Proposed Process). In contrast, TDL and Ariosa's Harmony
test was found not to infringe. The Lo 2 and Lo 3 patents were
affirmed as valid, as were Quake patents (with permitted amend-
ments), and the IONA test was held to infringe all, including Lo 1. In
2018, Illumina and Premaitha settled all litigation and Premaitha
licensed Illumina's patent pool.49 However, like the United States,
there are other NIPT cases in progress.6 | PATENT PRACTICE IN AUSTRALIA
Patent 727919 is Australia's member of the 540 patent family. In
2016, Sequenom filed an infringement suit against Ariosa Diagnostics,
Sonic Healthcare and Clinical Laboratories in the Federal Court of
Australia. After a trial in 2018, judgement is reserved.
Australia has a broad requirement that subject matter is a “manner
of manufacture”, akin to the “composition of matter” requirement inUS law. A 1959 decision of the Australian High Court in National
Research and Development Corporation v Commissioner of Patents
(NRDC)50 remains the main authority on interpreting the manner of
manufacture requirement. Here, the claimed process was held to be
patentable because it produced a product that was an “artificially
created state of affairs” and “the significance of the product [was]
economic.” Over the years since NRDC, these twin requirements have
largely determined the manner of manufacture requirement.
In litigation relating to the Australian patent corresponding to
those considered in the US Myriad case, the only claim that was
challenged was a DNA sequence claim. The High Court of Australia
unanimously invalidated that claim in the Myriad patent, and held that
isolated DNA sequences are not patentable subject‐matter.51 The
High Court noted that satisfaction of the manner of manufacture test
requires that something is “made,” and that this “must be something
brought about by human action.”52 The court held that the substance
of the claims in the Myriad patent was the information embodied in
the arrangements of nucleotides, and this information was not made
by human action, but was instead discerned.24
While there have been some significant method‐related Australian
cases, until recently, none considered the specific issues raised in the
US case of Mayo about the patentability of methods applying a law
of nature. Beach J of the Australian Federal Court considered methods
of this nature in Meat and Livestock Australia v Cargill (Cargill).53 The
patent in issue included a series of method claims for identifying
bovine traits from nucleic acid samples using single nucleotide poly-
morphisms for managing, selecting, breeding, and cloning cattle. His
Honour rejected arguments that the claims involved simply the practi-
cal application of a naturally occurring phenomenon to a particular
use, and the patent was not invalidated on this basis.54 Beach J found
that the test inMayowas “too sweeping for [him] to work out whether
[he was] acting consistently or inconsistently with its spirit” when
determining what it takes to transform an unpatentable law of nature
into a patent‐eligible application55
Although the Cargill decision delivered by Beach J is likely to be
appealed, it is notable that he is the judge who has also been allocated
the Sequenom v Ariosa trial. That litigation will present Australian
courts with an opportunity to consider the patent‐eligibility of method
claims in the context of NIPT. Even so, it is likely to take several years
before there is a definitive ruling as to the patentability of methods of
diagnosis in Australia, assuming that the parties pursue court proceed-
ings and appeals with the same passion as they have done in the
United States.7 | IMPLICATIONS FOR THE FIELD
As is evident, there are many patents in the field of NIPT. The 540
patent has already been invalidated in the United States, with the
corresponding patents the subject of ongoing litigation in Europe
and Australia. In any case, the patent expired in 2017, although the
damages payable for infringement during its life are considerable,
making continuing litigation worthwhile. Moreover, there are also
HAWKINS ET AL. 5other patents relevant to NIPT held by a number of parties that are in
litigation, and others still are not yet being litigated. Some of these
form part of the patent cross‐licensing between Sequenom and
Illumina, and others are held by other parties offering commercial
testing. Many of these patents are likely to be valid and enforceable,
at least in part, and in some jurisdictions.
The validity of patents varies across different jurisdictions, with
implications for the global NIPT market. At present, there is the distinct
possibility that patents that are valid in Europe and Australia may be
invalid in the United States. A valid patent gives the rights‐holder the
ability to limit the actions of competitors or to require licenses and roy-
alty payments in the jurisdictions where that patent is valid. A patent
position therefore confers a commercial advantage, but it remains to
be seen how variation in patent portfolios internationally might influ-
ence competitive strengths in the global NIPT market. Indeed, some
companies appear to be targeting markets where there is greater
freedom to operate in the absence of patents held by their competitors
(eg, in the Middle East or in parts of Asia), with the arguable collateral
benefit of increased access in markets that have traditionally been
lesser served by biomedical innovation. At present, there is uncertainty
while court decisions remain outstanding. As litigation is resolved,
either through judgments or through settlements, the relationships
between patent holders and users of patented technology will become
more certain. However, commercial uncertainty will operate as a
background to the delivery of tests for some time.
The many patents held by multiple parties make it likely that in the
long run, numerous providers will remain in the market. The extensive
patent portfolio and cross‐licensing agreement between Illumina and
Sequenom, which includes the 540 patent, will likely afford them a
strong position in the market, and the ability to demand licensing from
other NIPT providers (or even prevent them operating in some
jurisdictions). Although other patents are also significant, they are
narrower in scope, and therefore are unlikely to enable one party to
operate to the exclusion of all others. Thus, several parties will likely
continue to offer testing, with cross‐licensing or modification of test-
ing methods to avoid infringement as necessary.
In addition to the commercial providers offering NIPT, many public
sector providers also perform NIPT, either as partners with the
commercial providers or by developing their own NIPT. Increasingly,
commercial entities are entering new markets where they have not pre-
viously had a large presence, including, for example, some European
countries where genetic testing has been almost exclusively through
public sector laboratories. The nature of NIPT technology, coupled with
patents, means that commercial parties have been able to bargain for
samples to be sent to their laboratories for testing or for the licensing
of their “black box” technology transfer into public sector laboratories.
The translation of NIPT technology into clinical application has
been very rapid. Pregnant women may access NIPT on a private, pay
for service basis, or through insurance coverage. Increasingly, public
healthcare systems, especially in Europe, provide access to NIPT test-
ing for certain patient groups,56,57 with the likelihood that other coun-
tries will roll out public sector programmes in the next few years.58,59
However, access toNIPT is limited on the basis of cost inmany countries.The contribution of patents to the cost of testing is a complex economic
question, and there is no direct or linear relationship. However, it is inev-
itable that the high costs of litigation and patent enforcement will be
passed on to those who pay for tests. At the same time, the competition
between numerous commercial parties offering testing will serve to keep
commercial prices down. While it is not possible to offer definitive
answers about the impact of patents on patient access to testing, as that
is dependent on factors including how private and public payors cover
these tests, it will continue to be important to monitor options of
technologies and tests available to public healthcare systems, as the pat-
ent issues are resolved through judicial decisions and settlements.8 | CONCLUSION
The patent situation in NIPT remains in flux. Uncertainty in relation to
the enforceability and scope of patents will persist for the foreseeable
future. Patents are unlikely to result in a monopoly for a single
provider, however, given the cross‐licensing of crucial patents,
jurisdictional differences in patent eligibility, the plurality of providers
and testing technologies, and the diverse public and private sector
entities involved in NIPT.
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